Legg Mason Low Volatility High Div ETF (LVHD) formed double top with $31.91 target or 8.00% above today’s $29.55 share price. Legg Mason Low Volatility High Div ETF (LVHD) has $552.18 million valuation. The ETF increased 0.07% or $0.02 during the last trading session, reaching $29.55. About 23,662 shares traded. Legg Mason Low Volatility High Div ETF (NASDAQ:LVHD) has declined 2.89% since January 13, 2018 and is downtrending. It has underperformed by 2.89% the S&P500.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) had a decrease of 7.16% in short interest. APLS’s SI was 2.29M shares in January as released by FINRA. Its down 7.16% from 2.47M shares previously. With 226,800 avg volume, 10 days are for Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s short sellers to cover APLS’s short positions. The SI to Apellis Pharmaceuticals Inc’s float is 9.81%. The stock increased 7.01% or $0.98 during the last trading session, reaching $14.97. About 817,299 shares traded or 139.28% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has risen 28.52% since January 13, 2018 and is uptrending. It has outperformed by 28.52% the S&P500. Some Historical APLS News: 30/04/2018 – Apellis Pharmaceuticals 1Q Loss/Shr 43c; 26/03/2018 – APELLIS PHARMACEUTICALS INC APLS.O : CITIGROUP RAISES TARGET PRICE TO $30 FROM $23; 23/04/2018 – DJ Apellis Pharmaceuticals Inc, Inst Holders, 1Q 2018 (APLS); 16/04/2018 – Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculi; 16/04/2018 – APELLIS PHARMACEUTICALS INC – EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE; 16/04/2018 – Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab; 19/03/2018 – Apellis Pharmaceuticals 4Q Loss $18.3M; 30/04/2018 – Apellis Pharma Had Cash Position of $152.9 Million at Qtr-End; 19/03/2018 APELLIS PHARMACEUTICALS INC QTRLY SHR LOSS $0.61; 16/04/2018 – APELLIS – IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB

More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: Seekingalpha.com which released: “Planned equity offering roundup – healthcare – Seeking Alpha” on December 30, 2018, also Nasdaq.com with their article: “Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy – Nasdaq” published on December 20, 2018, Nasdaq.com published: “Apellis Pharmaceuticals to Present at the 37th Annual JP Morgan Healthcare Conference – Nasdaq” on January 02, 2019. More interesting news about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were released by: Seekingalpha.com and their article: “Apellis Pharma’s APL-2 an Orphan Drug in U.S. for kidney disorder – Seeking Alpha” published on December 20, 2018 as well as Benzinga.com‘s news article titled: “58 Biggest Movers From Yesterday – Benzinga” with publication date: December 20, 2018.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $841.95 million. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.





Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *